Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation
Status:
Not yet recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
This study is phase 2 open-label, single-arm, multi-center clinical trial to evaluate the
efficacy and safety of Camostat mesylate in patients with Protein-losing enteropathy after
Fontan operation.